CD276 and bladder transitional cell carcinoma: The PFI analysis showed that CD276 acts as a hazardous element in patients with BLCA, HNSC, ACC, LGG, MESO, PAAD and UVM, whereas it serves as a protective element for patients with DLBC (Fig. 9B).